SCHEMBL15940607

SCHEMBL15940607

C#Cc1nc(-c2ccccc2)cc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.44
ACHE P22303 1/20 0.43
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 2/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PDE10A Q9Y233 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
DHODH Q02127 1/20 0.38
MAPT P10636 2/20 0.38
AGTR1 P30556 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30616770 0.73 KDM4E (0.53) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL29446790 0.73 KDM4E (0.53) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL3318116 0.73 KDM4E (0.53) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL31388225 0.72 MEN1 (0.55) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL28880193 0.72 ADORA3 (0.51) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL29177933 0.72 ACHE (0.52) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL696285 0.72 ACHE (0.56) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL786133 0.72 MEN1 (0.55) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL21033710 0.72 MEN1 (0.50) ADORA3ACHEIDO1TDO2SMN1; SMN2
SCHEMBL6382426 0.72 IDO1 (0.54) ADORA3ACHEIDO1TDO2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9879004-B2 Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 MERCK PATENT GMBH (DE) 2018-01-30 US disclosed
US-20150376182-A1 Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 MERCK PATENT GMBH (DE) 2015-12-31 US disclosed
EP-2953933-A1 SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 Merck Patent GmbH (DE) 2015-12-16 EP disclosed
WO-2014121883-A1 SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 MERCK PATENT GMBH (DE) 2014-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376182-A1 Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 GRM4, GRIA4, GRIK4 ADORA3 529/4885ACHE 1519/4885IDO1 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.